Sort   by:  
 Page size 
Changes in cellular lipid metabolism are a common feature in most solid tumors, which occur already in early stages of the tumor progression. However, it remains unclear if the tumor-specific lipid changes can be detected at the level of systemic lipid metabolism. The objective of this study was to ...
2014-06-17 | MTBLS92 | MetaboLights
Pancreatic cancer (Pancreatic Ductal Adenocarcinoma; PDAC) is highly resistant to chemotherapy. Effective alternative therapies have yet to emerge, and therefore, chemotherapy remains the best available systematic treatment. The discovery of safe and available adjuncts that can improve chemotherapeu...
2022-10-18 | MTBLS6000 | MetaboLights

Understanding how the microbiota produces regulatory metabolites is of significance for cancer and cancer therapy. Using a host-microbe-drug-nutrient 4-way screening approach, we evaluated the role of nutrition at the molecular level in the context of 5-fluorouracil toxicity. Notably, our screens...

2025-09-16 | MTBLS9991 | MetaboLights
Chemotherapy combined with checkpoint blockade antibodies targeting programmed cell death protein (PD-1) has achieved remarkable success in non-small cell lung cancer (NSCLC). However, few patients benefit from long-term treatment. Therefore, biomarkers capable of guiding the optimal therapeutic sel...
2025-06-16 | MTBLS11232 | MetaboLights

Understanding how the microbiota produces regulatory metabolites is of significance for cancer and cancer therapy. Using a host-microbe-drug-nutrient 4-way screening approach, we evaluated the role of nutrition at the molecular level in the context of 5-fluorouracil toxicity. Notably, our screens...

2025-09-16 | MTBLS9994 | MetaboLights

Background: Breast cancer progression and treatment are increasingly linked to systemic metabolic and microbial alterations. Previous studies have identified distinct gut microbiome profiles and serum metabolite shifts in breast cancer patients compared to healthy individuals, yet longitudi...

2026-05-08 | MTBLS13634 | MetaboLights
Cancer cells are known to reprogram their metabolism to adapt to adverse conditions dictated by tumor growth and microenvironment. A subtype of cancer cells with stem-like properties, known as cancer stem cells (CSC), is thought to be responsible for tumor recurrence. In this study, we demonstrated ...
2019-08-19 | MTBLS678 | MetaboLights

Gut microbiota has been reported to be associated with the host’s immune system and immunotherapy response, as well as immune-related adverse events (irAEs). Additionally, gut microbial metabolites have various immunomodulatory effects. Our study focused on the differences in gut microbiota and t...

2025-12-23 | MTBLS13557 | MetaboLights

Gemcitabine always has a short-term immune effect, and we consider using oral polysaccharides to lengthen its immune effect by modulating gut microbiotas. To verify this, we built a breast cancer mice model in situ, oral polysaccharides and a low-dose of Gemcitabine were administrated, ...

2025-06-14 | MTBLS12563 | MetaboLights
There is large variability among lung squamous cell carcinoma (SCC) patients in response to treatment with cisplatin based chemotherapy. LncRNAs is potentional a new type of predictive marker that can identify subgroups of patients who benefit from chemotherapy and it will have great value for treat...
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size